Placenta growth factor in sickle cell disease: Association with hemolysis and inflammation

Julia Elizabeth Brittain, Ben Hulkower, Susan K. Jones, Dell Strayhorn, Laura De Castro, Marilyn J. Telen, Eugene P. Orringer, Alan Hinderliter, Kenneth I. Ataga

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Placenta growth factor (PIGF) is released by immature erythrocytes and is elevated in sickle cell disease (SCD). Previous data generated in vitro suggest that PlGF may play a role in the pathophysiology of SCD-associated pulmonary hypertension (PHT) by inducing the release of the vasoconstrictor, endothelin-1. In this crosssectional study of 74 patients with SCD, we confirm that PlGF is significantly elevated in SCD compared with healthy control subjects. We found significantly higher levels of PlGF in SCD patients with PHT but observed no association of PlGF with the frequency of acute pain episodes or history of acute chest syndrome. The observed correlation between PlGF and various measures of red cell destruction suggests that hemolysis, and the resultant erythropoietic response, results in the up-regulation of PlGF. Although relatively specific, PlGF, as well as N-terminal pro-brain natriuretic peptide and soluble vascular cell adhesion molecule, has low predictive accuracy for the presence of PHT. Prospective studies are required to conclusively define the contribution of PlGF to the pathogenesis of PHT and other hemolytic complications in SCD.

Original languageEnglish (US)
Pages (from-to)2014-2020
Number of pages7
JournalBlood
Volume115
Issue number10
DOIs
StatePublished - Mar 11 2010

Fingerprint

Sickle Cell Anemia
Hemolysis
Intercellular Signaling Peptides and Proteins
Inflammation
Pulmonary Hypertension
Acute Chest Syndrome
Vascular Cell Adhesion Molecule-1
Brain Natriuretic Peptide
Acute Pain
Vasoconstrictor Agents
Endothelin-1
Placenta Growth Factor
Healthy Volunteers
Up-Regulation
Erythrocytes
Cells
Prospective Studies

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Brittain, J. E., Hulkower, B., Jones, S. K., Strayhorn, D., De Castro, L., Telen, M. J., ... Ataga, K. I. (2010). Placenta growth factor in sickle cell disease: Association with hemolysis and inflammation. Blood, 115(10), 2014-2020. https://doi.org/10.1182/blood-2009-04-217950

Placenta growth factor in sickle cell disease : Association with hemolysis and inflammation. / Brittain, Julia Elizabeth; Hulkower, Ben; Jones, Susan K.; Strayhorn, Dell; De Castro, Laura; Telen, Marilyn J.; Orringer, Eugene P.; Hinderliter, Alan; Ataga, Kenneth I.

In: Blood, Vol. 115, No. 10, 11.03.2010, p. 2014-2020.

Research output: Contribution to journalArticle

Brittain, JE, Hulkower, B, Jones, SK, Strayhorn, D, De Castro, L, Telen, MJ, Orringer, EP, Hinderliter, A & Ataga, KI 2010, 'Placenta growth factor in sickle cell disease: Association with hemolysis and inflammation', Blood, vol. 115, no. 10, pp. 2014-2020. https://doi.org/10.1182/blood-2009-04-217950
Brittain JE, Hulkower B, Jones SK, Strayhorn D, De Castro L, Telen MJ et al. Placenta growth factor in sickle cell disease: Association with hemolysis and inflammation. Blood. 2010 Mar 11;115(10):2014-2020. https://doi.org/10.1182/blood-2009-04-217950
Brittain, Julia Elizabeth ; Hulkower, Ben ; Jones, Susan K. ; Strayhorn, Dell ; De Castro, Laura ; Telen, Marilyn J. ; Orringer, Eugene P. ; Hinderliter, Alan ; Ataga, Kenneth I. / Placenta growth factor in sickle cell disease : Association with hemolysis and inflammation. In: Blood. 2010 ; Vol. 115, No. 10. pp. 2014-2020.
@article{a6e70275b3f44992b255b4affb8be800,
title = "Placenta growth factor in sickle cell disease: Association with hemolysis and inflammation",
abstract = "Placenta growth factor (PIGF) is released by immature erythrocytes and is elevated in sickle cell disease (SCD). Previous data generated in vitro suggest that PlGF may play a role in the pathophysiology of SCD-associated pulmonary hypertension (PHT) by inducing the release of the vasoconstrictor, endothelin-1. In this crosssectional study of 74 patients with SCD, we confirm that PlGF is significantly elevated in SCD compared with healthy control subjects. We found significantly higher levels of PlGF in SCD patients with PHT but observed no association of PlGF with the frequency of acute pain episodes or history of acute chest syndrome. The observed correlation between PlGF and various measures of red cell destruction suggests that hemolysis, and the resultant erythropoietic response, results in the up-regulation of PlGF. Although relatively specific, PlGF, as well as N-terminal pro-brain natriuretic peptide and soluble vascular cell adhesion molecule, has low predictive accuracy for the presence of PHT. Prospective studies are required to conclusively define the contribution of PlGF to the pathogenesis of PHT and other hemolytic complications in SCD.",
author = "Brittain, {Julia Elizabeth} and Ben Hulkower and Jones, {Susan K.} and Dell Strayhorn and {De Castro}, Laura and Telen, {Marilyn J.} and Orringer, {Eugene P.} and Alan Hinderliter and Ataga, {Kenneth I.}",
year = "2010",
month = "3",
day = "11",
doi = "10.1182/blood-2009-04-217950",
language = "English (US)",
volume = "115",
pages = "2014--2020",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Placenta growth factor in sickle cell disease

T2 - Association with hemolysis and inflammation

AU - Brittain, Julia Elizabeth

AU - Hulkower, Ben

AU - Jones, Susan K.

AU - Strayhorn, Dell

AU - De Castro, Laura

AU - Telen, Marilyn J.

AU - Orringer, Eugene P.

AU - Hinderliter, Alan

AU - Ataga, Kenneth I.

PY - 2010/3/11

Y1 - 2010/3/11

N2 - Placenta growth factor (PIGF) is released by immature erythrocytes and is elevated in sickle cell disease (SCD). Previous data generated in vitro suggest that PlGF may play a role in the pathophysiology of SCD-associated pulmonary hypertension (PHT) by inducing the release of the vasoconstrictor, endothelin-1. In this crosssectional study of 74 patients with SCD, we confirm that PlGF is significantly elevated in SCD compared with healthy control subjects. We found significantly higher levels of PlGF in SCD patients with PHT but observed no association of PlGF with the frequency of acute pain episodes or history of acute chest syndrome. The observed correlation between PlGF and various measures of red cell destruction suggests that hemolysis, and the resultant erythropoietic response, results in the up-regulation of PlGF. Although relatively specific, PlGF, as well as N-terminal pro-brain natriuretic peptide and soluble vascular cell adhesion molecule, has low predictive accuracy for the presence of PHT. Prospective studies are required to conclusively define the contribution of PlGF to the pathogenesis of PHT and other hemolytic complications in SCD.

AB - Placenta growth factor (PIGF) is released by immature erythrocytes and is elevated in sickle cell disease (SCD). Previous data generated in vitro suggest that PlGF may play a role in the pathophysiology of SCD-associated pulmonary hypertension (PHT) by inducing the release of the vasoconstrictor, endothelin-1. In this crosssectional study of 74 patients with SCD, we confirm that PlGF is significantly elevated in SCD compared with healthy control subjects. We found significantly higher levels of PlGF in SCD patients with PHT but observed no association of PlGF with the frequency of acute pain episodes or history of acute chest syndrome. The observed correlation between PlGF and various measures of red cell destruction suggests that hemolysis, and the resultant erythropoietic response, results in the up-regulation of PlGF. Although relatively specific, PlGF, as well as N-terminal pro-brain natriuretic peptide and soluble vascular cell adhesion molecule, has low predictive accuracy for the presence of PHT. Prospective studies are required to conclusively define the contribution of PlGF to the pathogenesis of PHT and other hemolytic complications in SCD.

UR - http://www.scopus.com/inward/record.url?scp=77950435332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950435332&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-04-217950

DO - 10.1182/blood-2009-04-217950

M3 - Article

C2 - 20040765

AN - SCOPUS:77950435332

VL - 115

SP - 2014

EP - 2020

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -